Sugi Predict

Sugi Predict / Compounds / SCHEMBL540294

SCHEMBL540294

SCHEMBL540294

N#Cc1ccc(F)c(O)c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ P4HB P07237 4/20 0.51
▸ HSD17B14 Q9BPX1 1/20 0.51
▸ CA3 P07451 2/20 0.50
▸ CA6 P23280 2/20 0.50
▸ CA9 Q16790 2/20 0.50
▸ CA14 Q9ULX7 2/20 0.50
▸ CA5A P35218 1/20 0.50
▸ CA5B Q9Y2D0 1/20 0.50
▸ CA12 O43570 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ CYP19A1 P11511 1/20 0.46
▸ MMP3 P08254 1/20 0.41
▸ CXCR2 P25025 3/20 0.40
▸ CXCR1 P25024 2/20 0.40
▸ CYP2A6 P11509 1/20 0.39
▸ KIF11 P52732 1/20 0.39
▸ AR P10275 1/20 0.39
▸ HSD17B1 P14061 1/20 0.38
▸ HSD17B2 P37059 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29826346 0.82 P4HB (0.51) P4HBHSD17B14CA3CA6CA9
SCHEMBL200168 0.82 P4HB (0.51) P4HBHSD17B14CA3CA6CA9
SCHEMBL1477498 0.79 CYP11B1 (0.43) P4HBHSD17B14CA3CA6CA9
SCHEMBL29449995 0.78 CA12 (0.52) CA3CA6CA9CA14CA12
SCHEMBL217250 0.78 CA12 (0.52) CA3CA6CA9CA14CA12
SCHEMBL29416796 0.78 EGLN2 (0.44) CA3CA6CA9CA14CA12
SCHEMBL229147 0.78 EGLN2 (0.44) CA3CA6CA9CA14CA12
SCHEMBL21501364 0.78 TMPRSS4 (0.44) P4HBHSD17B14CXCR2CXCR1AR
SCHEMBL2797870 0.77 CA9 (0.50) P4HBHSD17B14CA3CA6CA9
SCHEMBL23271632 0.76 CA12 (0.50) CA3CA6CA9CA14CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111162313-A Polymer electrolyte and lithium ion battery 珠海冠宇电池有限公司 2020-05-15 — — CN claimed
CN-121591568-B Fluorine-containing hydroxybenzoic acid compound and preparation method thereof Fuxin Jinhongtai Chemical Co.,Ltd. (CN) 2026-05-29 — — CN disclosed
US-20260125378-A2 Heterocyclic Compounds BEONE MEDICINES I GMBH (CH) 2026-05-07 — — US disclosed
EP-4735423-A1 KV7 MODULATORS Saniona A/S (DK) 2026-05-06 — — EP disclosed
CN-121591568-A Fluorine-containing hydroxybenzoic acid compound and preparation method thereof 阜新金鸿泰化工有限公司 2026-03-03 — — CN disclosed
US-12503477-B2 Colony stimulating factor-1 receptor (CSF-1R) inhibitors GENZYME CORPORATION 2025-12-23 — — US disclosed
EP-4658650-A1 HETEROCYCLIC COMPOUNDS Beone Medicines I GmbH (CH) 2025-12-10 — — EP disclosed
US-20250353846-A1 Heterocyclic Compounds BEONE MEDICINES I GMBH (CH) 2025-11-20 — — US disclosed
US-20250188039-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2025-06-12 — — US disclosed
WO-2025003343-A1 KV7 MODULATORS SANIONA A/S (DK) 2025-01-02 — — WO disclosed
WO-2007136572-A2 ANTIDIABETIC BICYCLIC COMPOUNDS MERCK & CO., INC. (US) 2007-11-29 — — WO disclosed
WO-2007136572-A2 ANTIDIABETIC BICYCLIC COMPOUNDS MERCK & CO., INC. (US) 2007-11-29 — — WO disclosed
WO-2007136573-A2 ANTIDIABETIC BICYCLIC COMPOUNDS MERCK & CO., INC. (US) 2007-11-29 — — WO disclosed
US-20070265332-A1 Antidiabetic bicyclic compounds MERCK SHARP & DOHME LLC 2007-11-15 — — US disclosed
US-20070265332-A1 Antidiabetic bicyclic compounds MERCK SHARP & DOHME LLC 2007-11-15 — — US disclosed
US-20070265332-A1 Antidiabetic bicyclic compounds MERCK SHARP & DOHME LLC 2007-11-15 — — US disclosed
US-7259172-B2 phenyl or thien-2-yl substituted amide methyl phosphonate or phosphonyl halide derivatives; do not require a beta -lactam pharmacophore; bactericides; antibiotic resistance METHYLGENE INC. (CA) 2007-08-21 — — US disclosed
US-7259172-B2 phenyl or thien-2-yl substituted amide methyl phosphonate or phosphonyl halide derivatives; do not require a beta -lactam pharmacophore; bactericides; antibiotic resistance METHYLGENE INC. (CA) 2007-08-21 — — US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125378-A2 Heterocyclic Compounds NFATC1, CD4, MALT1 P4HB 2836/4885HSD17B14 250/4885CA3 837/4885
US-20070265332-A1 Antidiabetic bicyclic compounds GPR119, GPR65, FFAR4 P4HB 3648/4885HSD17B14 533/4885CA3 3113/4885
US-20250188039-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS DUT, TYMP, DPYD P4HB 2038/4885HSD17B14 853/4885CA3 2120/4885
US-20250353846-A1 Heterocyclic Compounds NFATC1, CD4, ACIN1 P4HB 4262/4885HSD17B14 1709/4885CA3 4552/4885
US-12503477-B2 Colony stimulating factor-1 receptor (CSF-1R) inhibitors CSF1R, CSF3R, IL1RN P4HB 4605/4885HSD17B14 3108/4885CA3 4878/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 P4HB 844/4885HSD17B14 729/4885CA3 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.